This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nishihori T, Komrokji R, Shain K, Anasetti C . Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50: 296–297.
Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 4086–4092.
Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014; 15: 333–342.
Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ . Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant 2012; 47: 804–809.
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229–1235.
Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German cooperative transplant study group. Biol Blood Marrow Transplant 2015; 21: 653–660.
Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J . Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004; 34: 923–928.
Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908–1918.
Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L et al. Complete remission of Waldenstrom macroglobulinemia with azacitidine and rituximab. J Clin Oncol 2011; 29: e696–e698.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
TS had a consulting role for Celgene Corporation, Germany and received financial travel support and lecture fees from Celgene Corporation, Germany. RF had a consulting role for Celgene Corporation, Germany and received honoraria, research funding and financial travel support from Celgene Corporation, Germany. UG received a speakers honorarium and research support from Celgene, Novartis and Janssen-Cilag. GK received financial travel support, research funding and lecture fees from Celgene Corporation. The remaining author declares no conflict of interest.
Additional information
Author contributions
TS and GK wrote the manuscript. All the authors gave final approval of the manuscript.
Rights and permissions
About this article
Cite this article
Schroeder, T., Fenk, R., Haas, R. et al. Reply to ‘Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome’. Bone Marrow Transplant 50, 1483–1485 (2015). https://doi.org/10.1038/bmt.2015.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.176